Cell>Point enters deal for commercialization of imaging agents

03/14/2013 | Business Wire

Cell>Point said it has secured a licensing deal with South Korean firm Hanmi Pharmaceutical. The agreement involves the development and commercialization of Cell>Point's cancer and cardiology imaging agent, to be developed through its ethylenedicysteine-glucosamine technology. The partnership will initially produce technetium-99m-labeled EC-G for SPECT and SPECT/CT uses. The collaboration will cover gallium-68-labeled EC-G for PET/CT imaging later on.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA